Halozyme Therapeutics (DE:RV7)
FRANKFURT:RV7

Halozyme Stock Price & Analysis

0 Followers

RV7 Stock Chart & Stats

Day’s Range€0 - €0
52-Week Range€28.46 - €54.40
Previous Close€54.4
Volume110.00
Average Volume (3M)102.00
Market CapN/A
Enterprise ValueN/A
Total Cash (Recent Filing)$265.58M
Total Debt (Recent Filing)$1.50B
Price to Earnings (P/E)N/A
Beta1.73
Next EarningsFeb 21, 2023
Next Dividend Ex-DateN/A
Dividend YieldN/A
EPS (TTM)N/A
Shares Outstanding135,213,058
R-SquaredN/A
Standard DeviationN/A
10 Day Avg. Volume64
30 Day Avg. Volume102
Price to Book (P/B)-7.34
Price to Sales (P/S)12.67
Price to Cash Flow (P/CF)33.70
P/FCF Ratio-10.10
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Price Target Upside1.65% Upside
Rating ConsensusStrong Buy
AlphaN/A
Number of Analyst Covering5


Financials


RV7 FAQ

What was Halozyme’s price range in the past 12 months?
Halozyme lowest stock price was €28.46 and its highest was €54.40 in the past 12 months.
    What is Halozyme’s market cap?
    Currently, no data Available
    When is Halozyme’s upcoming earnings report date?
    Halozyme’s upcoming earnings report date is Feb 21, 2023 which is in 81 days.
      How were Halozyme’s earnings last quarter?
      Halozyme released its earnings results on Nov 08, 2022. The company reported €0.422 earnings per share for the quarter, beating the consensus estimate of €0.347 by €0.075.
        Is Halozyme overvalued?
        According to Wall Street analysts Halozyme’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
          Does Halozyme pay dividends?
          Halozyme does not currently pay dividends.
          What is Halozyme’s EPS estimate?
          Halozyme’s EPS estimate is €0.26.
            How many shares outstanding does Halozyme have?
            Currently, no data Available
            What happened to Halozyme’s price movement after its last earnings report?
            Halozyme reported an EPS of €0.422 in its last earnings report, beating expectations of €0.347. Following the earnings report the stock price went down -0.64%.
              Which hedge fund is a major shareholder of Halozyme?
              Among the largest hedge funds holding Halozyme’s share is Driehaus Capital Management LLC. It holds Halozyme’s shares valued at 53M.

                ---

                Halozyme Stock Smart Score

                10
                Outperform
                1
                2
                3
                4
                5
                6
                7
                8
                9
                10
                The Halozyme Holdings stock analysis is based on the TipRanks Smart Score which is derived from 6 unique data sets including Analyst recommendations, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.
                Learn more about TipRanks Smart Score

                Company Description

                Halozyme Therapeutics

                Halozyme Therapeutics, Inc. is a biopharmaceutical company, which engages in research, development & commercialization of human enzymes and drug candidates. It focuses on novel oncology therapies that target the tumor microenvironment. Its products include PEGPH20, HTI-1511, PEG-ADA2, and HYLENEX recombinant. The company was founded by Gregory Ian Frost on February 26, 1998 and is headquartered in San Diego, CA.

                ---

                Forecast EPS vs Actual EPS


                Similar Stocks
                Company
                Price & Change
                Follow
                Incyte
                United Therapeutics
                Neurocrine
                Sarepta Therapeutics
                Legend Biotech

                Popular Stocks

                ---
                What's Included in PREMIUM?
                Make informed decisions based on Top Analysts' activity
                Know what industry insiders are buying
                Get actionable alerts from top Wall Street Analysts
                Find out before anyone else which stock is going to shoot up
                Get powerful stock screeners & detailed portfolio analysis